Novavax (NASDAQ:NVAX) launches a U.K.-based Phase 3 clinical trial evaluating COVID-19 vaccine candidate NVX-CoV2373 in up to 10K adult (ages 18-84) volunteers.
Enrollment in the study, being conducted in partnership with the U.K. government's Vaccines Taskforce, should be completed over the next 4-6 weeks. Results will support marketing applications in the U.K., Europe and other countries.
NVX-CoV2373 is a stable prefusion protein based on the company's recombinant protein nanoparticle technology that includes its proprietary Matrix adjuvant. The vaccine can be stored at 2°C to 8°C, allowing for distribution using standard vaccine channels.
READ FULL ARTICLE HERE
